MedTrace Logo

"cindilizumab + Bevacizumab + Coenzyme I for Injection" in Unresectable Hepatocellular Carcinoma

NCT06590844 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2024-09-19

No results posted yet for this study

Summary

This study is a single-arm, single-center, non-randomized, open-label study. A total of 37 patients with locally advanced or metastatic HCC who have not received systemic therapy, are not suitable for radical surgical resection or local treatment, or have disease progression after surgical resection or local treatment, the efficacy and safety of "cindilizumab + bevacizumab + coenzyme I for injection" are initially explored.

Conditions

Interventions

DRUG

Injectable coenzyme I

On the first day, we will treat patients with Tybo Sulsintilimab ® 200mg IV and Dalutin ® Bevacizumab 15mg/kg IV every 21 days. The first to third days were treated with injectable coenzyme I, 100mg/day IV, every 21 days as a cycle.

Sponsors & Collaborators

  • Anhui Provincial Hospital

    lead OTHER_GOV

Principal Investigators

  • Liangxin Liu, Professor · AnhuiI Provincial Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Days
Max Age
80 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-19
Primary Completion
2026-03-31
Completion
2026-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06590844 on ClinicalTrials.gov